机器人辅助根治性膀胱切除术后前瞻性实施阿哌沙班方案的结果
本研究回顾性分析2018至2022年在本中心接受机器人辅助根治性膀胱切除术(RARC)患者的 prospectively 收集数据,比较出院后口服阿哌沙班2.5 mg每日两次共21天与依诺肝素40 mg每日一次对静脉血栓栓塞症(VTE)的预防效果。结果显示两组90天内症状性VTE发生率无统计学显著差异(阿哌沙班组1.6% vs 依诺肝素组3.2%,P=0.5),阿哌沙班在RARC术后VTE预防中似乎安全有效。
要点
- 阿哌沙班组90天VTE发生率1.6%,依诺肝素组3.2%,差异无统计学意义(P=0.5)。
- 按EAU风险分层后两组VTE率仍无统计学显著差异(P=0.5)。
- 多因素logistic回归未发现与主要结局相关的变量。
核心结论
- 阿哌沙班与依诺肝素预防RARC患者VTE的发生率无统计学显著差异;阿哌沙班在RARC术后VTE预防中似乎安全有效。
研究设计与样本
- 回顾性分析2018年至2022年在本三级医疗中心接受RARC的所有患者的前瞻性收集数据。
- 阿哌沙班组为2021年10月起前瞻性实施方案的患者,出院后口服阿哌沙班2.5 mg每日两次共21天;依诺肝素组为2021年10月前接受依诺肝素40 mg每日一次的患者。
- 共124例接受阿哌沙班预防,250例接受依诺肝素预防。
主要发现
- 术后90天内共10例(2.7%)发生VTE:阿哌沙班组2例(1.6%)vs 依诺肝素组8例(3.2%),P=0.5。
- 按欧洲泌尿外科学会风险分层,阿哌沙班组高危+中危VTE率2.7% vs 低危1.1%(P=0.5);依诺肝素组高危+中危4.3% vs 低危2.5%(P=0.5)。
- 多因素logistic回归未发现与主要结局相关的变量。
关键数值与推荐
- 主要结局为RARC术后90天内经明确影像学确认的症状性VTE发生率。
- 次要结局包括术后30天内大出血、并发症、再入院和死亡率。
临床怎么用
- 作者认为阿哌沙班在RARC术后VTE预防中似乎安全有效。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To compare the safety and efficacy of oral apixaban with that of injectable enoxaparin after robot-assisted radical cystectomy (RARC) for venous thromboembolism (VTE) thromboprophylaxis. MATERIALS AND METHODS: We conducted a retrospective review of prospectively collected data for all RARC patients treated at our tertiary care centre between 2018 and 2022. The study included two groups: patients who were subject to a prospectively implemented protocol from October 2021 to the present, comprising a 21-day postoperative course of apixaban 2.5 mg twice daily after discharge, and patients treated prior to October 2021 who received enoxaparin 40 mg daily. Baseline demographics and clinical characteristics, such as VTE (defined as deep vein thrombosis and pulmonary embolism), were analysed. The primary outcome was incidence of symptomatic VTE confirmed with definitive imaging within 90 days of RARC. Secondary outcomes included major bleeding, complications, readmission, and mortality within 30 days postoperatively. Descriptive statistics included baseline patient characteristics, operative information and complications. Differences in baseline characteristics and postoperative data were compared between groups. Multivariate logistic regression was used to determine associations between variables and the primary outcome. RESULTS: A total of 124 patients received apixaban and 250 patients received enoxaparin prophylaxis. Ten patients (2.7%) experienced a VTE within 90 days postoperatively (two [1.6%] apixaban group vs eight [3.2%] enoxaparin group; P = 0.5). After patient stratification into European Association of Urology risk groups, no statistically significant difference in VTE rates was seen between groups in the apixaban (2.7% high- + intermediate-risk group vs 1.1% low-risk group; P = 0.5) and enoxaparin cohorts (4.3% high- + intermediate-risk group vs 2.5% low-risk group; P = 0.5). On multivariate logistic regression, no variables were associated with the development of the primary outcome. CONCLUSION: Prophylaxis with apixaban and enoxaparin showed no statistically significant differences in VTE rates among RARC patients. Apixaban appears to be safe and effective for VTE prophylaxis after RARC.
引用
- Rich JM, Elkun Y, Geduldig J, et al. Outcomes from a prospectively implemented protocol using apixaban after robot-assisted radical cystectomy. BJU Int. 2023. PMID: 37186173. doi:10.1111/bju.16036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。